OpenAlex
PricingAboutJobs
Log inGet started
Author

Marc Oliva

Institutions: Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia
Observed institutions: Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia
ORCID: 0000-0001-5352-8130
Observed ORCID: 0000-0001-5352-8130
OpenAlex ID: A5137146122
Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).
2026 · Anna Spreafico, Khalil Sultanem, et al. · Journal of Clinical Oncology · 3
Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Efficacy by surgical outcomes in the phase 3 KEYNOTE-689 trial.
2026 · Douglas Adkins, Robert I. Haddad, et al. · Journal of Clinical Oncology · 2
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial
2026 · Hye Ryun Kim, Marc Oliva, et al. · European Journal of Cancer · 1
Works count: 3
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms